Fredag 20 November | 21:06:36 Europe / Stockholm
Est. tid*
2027-02-25 08:00 Bokslutskommuniké 2026
2026-11-26 08:00 Kvartalsrapport 2026-Q3
2026-11-02 - Extra Bolagsstämma 2026
2026-08-27 - Kvartalsrapport 2026-Q2
2026-05-28 - X-dag ordinarie utdelning SANION 0.00 SEK
2026-05-27 - Årsstämma
2026-05-26 - Kvartalsrapport 2026-Q1
2026-02-26 - Bokslutskommuniké 2025
2025-11-27 - Kvartalsrapport 2025-Q3
2025-08-28 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning SANION 0.00 SEK
2025-05-28 - Årsstämma
2025-05-28 - Kvartalsrapport 2025-Q1
2025-02-27 - Bokslutskommuniké 2024
2024-11-28 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-29 - Kvartalsrapport 2024-Q1
2024-05-27 - X-dag ordinarie utdelning SANION 0.00 SEK
2024-05-25 - Årsstämma
2024-02-29 - Bokslutskommuniké 2023
2024-01-16 - Extra Bolagsstämma 2024
2023-11-30 - Kvartalsrapport 2023-Q3
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-25 - Årsstämma
2023-05-25 - Kvartalsrapport 2023-Q1
2023-05-24 - X-dag ordinarie utdelning SANION 0.00 SEK
2023-02-23 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-08-18 - Extra Bolagsstämma 2022
2022-05-27 - X-dag ordinarie utdelning SANION 0.00 SEK
2022-05-25 - Årsstämma
2022-05-25 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-09-16 - Extra Bolagsstämma 2021
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning SANION 0.00 SEK
2021-05-26 - Årsstämma
2021-05-26 - Kvartalsrapport 2021-Q1
2021-03-17 - Bokslutskommuniké 2020
2020-11-30 - Kvartalsrapport 2020-Q3
2020-10-23 - Extra Bolagsstämma 2020
2020-08-27 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning SANION 0.00 SEK
2020-05-06 - Årsstämma
2020-05-06 - Kvartalsrapport 2020-Q1
2020-02-07 - Extra Bolagsstämma 2019
2020-02-07 - Bokslutskommuniké 2019
2019-11-13 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-05-31 - X-dag ordinarie utdelning SANION 0.00 SEK
2019-05-29 - Årsstämma
2019-05-29 - Kvartalsrapport 2019-Q1
2019-02-21 - Bokslutskommuniké 2018
2018-11-14 - Kvartalsrapport 2018-Q3
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning SANION 0.00 SEK
2018-05-24 - Årsstämma
2018-05-24 - Kvartalsrapport 2018-Q1
2018-02-21 - Bokslutskommuniké 2017
2018-01-19 - Extra Bolagsstämma 2018
2017-11-15 - Kvartalsrapport 2017-Q3
2017-08-23 - Kvartalsrapport 2017-Q2
2017-05-24 - X-dag ordinarie utdelning SANION 0.00 SEK
2017-05-23 - Årsstämma
2017-05-11 - Kvartalsrapport 2017-Q1
2017-02-21 - Bokslutskommuniké 2016
2016-10-13 - Extra Bolagsstämma 2016
2016-05-11 - X-dag ordinarie utdelning SANION 0.00 SEK
2016-05-10 - Årsstämma
2016-05-10 - Kvartalsrapport 2016-Q1
2016-02-19 - Bokslutskommuniké 2015
2015-11-20 - Kvartalsrapport 2015-Q3
2015-09-04 - Extra Bolagsstämma 2015
2015-08-31 - Kvartalsrapport 2015-Q2
2015-05-21 - X-dag ordinarie utdelning SANION 0.00 SEK
2015-05-20 - Årsstämma
2015-05-20 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-11-21 - Kvartalsrapport 2014-Q3
2014-08-22 - Kvartalsrapport 2014-Q2
LandDanmark
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Saniona är verksamt inom bioteknikbranschen och fokuserar på utveckling av behandlingar för neurologiska och psykiatriska sjukdomar. Bolaget forskar på nya terapier som kan förbättra patientresultat och livskvalitet. Verksamheten är global med en huvudsaklig närvaro i Europa och Nordamerika. Saniona grundades 2011 och har sitt huvudkontor i Glostrup, Danmark.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Saniona receives FDA clearance to initiate Phase 1 of SAN2465

2026-11-16 08:00:00

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on neurological and psychiatric disorders, today announces that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SAN2465, allowing Saniona to initiate a Phase 1 study in healthy volunteers. SAN2465 is being developed as a rapid-acting oral treatment for major depressive disorder (MDD), and the first participant is expected to be dosed before year-end.

“We are excited to initiate the clinical development of SAN2465 in MDD” said Pierandrea Muglia, Chief Medical Officer of Saniona. “The Phase 1 study will assess safety and pharmacokinetics while exploring effects on brain activity and cognition to help guide dose selection for studies in patients. Our ambition is to deliver rapid antidepressant efficacy comparable to ketamine and esketamine in an oral treatment that patients could take at home. We expect to dose the first participant before year-end.”

The Phase 1 study will include single ascending dose (SAD) and multiple ascending dose (MAD) parts and evaluate the safety, tolerability and pharmacokinetics of SAN2465 in healthy volunteers. Cognitive testing and pharmacodynamic assessments, including quantitative EEG, will explore its effects on brain function across dose levels and support dose selection for future studies in patients.

More about Major Depressive Disorder
Depression affects hundreds of millions of people worldwide [1]. Conventional antidepressants have a delayed onset for several weeks. Many patients do not achieve adequate relief with existing treatments. Approximately one-third of adults receiving medication for MDD in the United States are estimated to have treatment-resistant depression [2]. Esketamine (Spravato®), the first approved rapid-acting antidepressant, reached worldwide sales of USD 1.7 billion in 2025 [3], highlighting the significant demand for fast-acting treatment options. However, due to risks including dissociation, sedation, respiratory depression, and abuse and misuse, esketamine is available in the U.S. only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program requiring administration and monitoring in a certified healthcare setting [4].

More about SAN2465
SAN2465 is a selective GABA-A α5 negative allosteric modulator being developed as a rapid acting oral treatment for MDD, with the potential to overcome limitations associated with ketamine and esketamine. In the chronic mild stress model, a well-established animal model of depression [5], a single oral dose of SAN2465 produced a rapid and sustained reversal of chronic stress-induced depressive-like symptoms, including anhedonia, anxiety and cognitive impairment. The onset and magnitude of these effects were comparable to ketamine. SAN2465 has also been shown to significantly enhance hippocampal synaptic plasticity, as measured by long-term potentiation (LTP).

GABA-A α5 receptors are highly expressed in the hippocampus and related limbic regions involved in emotional regulation, mood and cognition [6,7]. Through selective modulation of these receptors, SAN2465 has the potential to deliver rapid antidepressant efficacy while avoiding the dissociative and other adverse effects associated with NMDA receptor antagonists, potentially enabling oral treatment at home without the need for in-clinic administration and monitoring.

[1] World Health Organization. Depression fact sheet, September 2026.
https://www.who.int/news-room/fact-sheets/detail/depression

[2] Zhdanava M et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry 2021;82(2):20m13699

[3] Johnson & Johnson. Q4 and full-year 2025 results, January 2026

[4] SPRAVATO® (esketamine) US Prescribing Information, revised September 2026

[5] Willner P. Neurobiol Stress 2017;6:78–93

[6] Sur C et al. Brain Res 1999;822:265–270

[7] Atack JR. Pharmacol Ther 2010;125(1):11–26